Phaco after trab may increase bleb failure rates at 1 year, but not 2 years

Article

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recently published study.

Phacoemulsification done after trabeculectomy may significantly increase the rates of bleb failure in the following 12 months, but not at 24 months, according to a recent study published in Clinical & Experimental Ophthalmology.

For this retrospective case control study, Dan Q Nguyen, FRCOphth, and fellow researchers at the University of Melbourne and the Royal Victorian Eye & Ear Hospital, Melbourne, Australia, included 48 patients who had undergone trabeculectomy and ≥2 years of follow-up. Patients were classified into two groups: those who had phacoemusification subsequent to trabeculectomy (trab_phaco; n = 18), and those who were pseudophakic for >6 months preceding trabeculectomy (Phaco_trab; n = 30). These groups were matched for length of follow-up of 2 years from time of trabeculectomy.

Researchers found no significant differences between the groups in achieving the primary outcome measures of target IOP of criteria A ≤12 mmHg, criteria B ≤15 mmHg, or criteria C ≤18 mmHg with or without additional topical treatment at 12 months (P = 1.0) and at 24 months (P = 0.330). In the first 12 months, significantly more trabeculectomies failed in the Trab_phaco group and required additional intervention for IOP control compared with the Phaco_trab group (39% vs 10%; P = 0.028). This trend continued at 24 months, but no significant differences in failure rates were seen between the groups (P = 0.522).

To access this study, go to the journal's website.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.